Tanshinone ⅡA attenuates bleomycin-induced pulmonary fibrosis in rats

He,Huanyu; Tang,Haiying; Gao,Lili; Wu,Yun; Feng,Zhiqiang; Lin,Hongli; Wu,Taihua

doi:10.3892/mmr.2015.3333

Tanshinone ⅡA attenuates bleomycin-induced pulmonary fibrosis in rats

Authors:
- Huanyu He
- Haiying Tang
- Lili Gao
- Yun Wu
- Zhiqiang Feng
- Hongli Lin
- Taihua Wu
View Affiliations

Affiliations: Department of Respiratory Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China, Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China
Published online on: February 11, 2015 https://doi.org/10.3892/mmr.2015.3333
Pages: 4190-4196
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Idiopathic pulmonary fibrosis is a chronic and progressive fibrotic lung disorder with unknown etiology and a high mortality rate. Tanshinone ⅡA (Tan ⅡA) is a lipophilic diterpene extracted from the Chinese herb Salvia miltiorrhiza Bunge with diverse biological functions. The present study was conducted to evaluate the effects of Tan ⅡA on bleomycin (BLM)‑induced pulmonary fibrosis in rats. Rats received an intraperitoneal injection of Tan ⅡA and normal rats were used as controls. Severe pulmonary edema, inflammation and fibrosis were observed in the BLM‑treated rats and the counts of total cells, neutrophils and lymphocytes were significantly increased in the bronchoalveolar lavage fluids of those rats. These pathological changes were markedly attenuated by subsequent treatment with Tan ⅡA. In addition, BLM‑induced increased expression of tumor necrosis factor‑α, interleukin (IL)‑1β, IL‑6, cyclooxygenase‑2, prostaglandin E2, malondialdehyde, inducible nitric oxide synthase and nitric oxide in rats, which was also suppressed by Tan ⅡA injection. The present findings suggest therapeutic potential of Tan ⅡA for pulmonary fibrosis.

View Figures

View References

1	Wilson MS and Wynn TA: Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2:103–121. 2009. View Article : Google Scholar : PubMed/NCBI
2	du Bois RM: Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov. 9:129–140. 2010. View Article : Google Scholar : PubMed/NCBI
3	Wynn TA and Ramalingam TR: Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med. 18:1028–1040. 2012. View Article : Google Scholar : PubMed/NCBI
4	Bringardner BD, Baran CP, Eubank TD and Marsh CB: The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid Redox Signal. 10:287–301. 2008. View Article : Google Scholar
5	Kliment CR and Oury TD: Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic Biol Med. 49:707–717. 2010. View Article : Google Scholar : PubMed/NCBI
6	Fubini B and Hubbard A: Reactive oxygen species (ROS) and reactive nitrogen species (RNS) generation by silica in inflammation and fibrosis. Free Radic Biol Med. 34:1507–1516. 2003. View Article : Google Scholar : PubMed/NCBI
7	No authors listed. Regulatory watch: First drug for idiopathic pulmonary fibrosis approved in Japan. Nat Rev Drug Discov. 7:966–967. 2008. View Article : Google Scholar
8	Moran N: p38 kinase inhibitor approved for idiopathic pulmonary fibrosis. Nat Biotechnol. 29:3012011. View Article : Google Scholar : PubMed/NCBI
9	Zhou L, Zuo Z and Chow MS: Danshen: an overview of its chemistry, pharmacology, pharmacokinetics and clinical use. J Clin Pharmacol. 45:1345–1359. 2005. View Article : Google Scholar : PubMed/NCBI
10	Chiu SC, Huang SY, Chen SP, Su CC, Chiu TL and Pang CY: Tanshinone IIA inhibits human prostate cancer cells growth by induction of endoplasmic reticulum stress in vitro and in vivo. Prostate Cancer Prostatic Dis. 16:315–322. 2013. View Article : Google Scholar : PubMed/NCBI
11	Shan YF, Shen X, Xie YK, et al: Inhibitory effects of tanshinone II-A on invasion and metastasis of human colon carcinoma cells. Acta Pharmacol Sin. 30:1537–1542. 2009. View Article : Google Scholar : PubMed/NCBI
12	Yu T, Zhou Z, Mu Y, de Lima Lopes G and Luo KQ: A novel anti-cancer agent, acetyltanshinone IIA, inhibits oestrogen receptor positive breast cancer cell growth by down-regulating the oestrogen receptor. Cancer Lett. 346:94–103. 2014. View Article : Google Scholar : PubMed/NCBI
13	Hong HJ, Liu JC, Cheng TH and Chan P: Tanshinone IIA attenuates angiotensin II-induced apoptosis via Akt pathway in neonatal rat cardiomyocytes. Acta Pharmacol Sin. 31:1569–1575. 2010. View Article : Google Scholar : PubMed/NCBI
14	Gao S, Liu Z, Li H, Little PJ, Liu P and Xu S: Cardiovascular actions and therapeutic potential of tanshinone IIA. Atherosclerosis. 220:3–10. 2012. View Article : Google Scholar
15	Chen Y, Wu X, Yu S, et al: Neuroprotection of tanshinone IIA against cerebral ischemia/reperfusion injury through inhibition of macrophage migration inhibitory factor in rats. PLoS One. 7:e401652012. View Article : Google Scholar : PubMed/NCBI
16	Liu Y, Chen H and Jiang Y: Effect of tanshinone IIA on CCl₄-induced liver fibrosis in rats. Zhong Yao Cai. 25:31–33. 2002.In Chinese.
17	Sun RF, Liu LX and Zhang HY: Effect of tanshinone II on hepatic fibrosis in mice. Zhongguo Zhong Xi Yi Jie He Za Zhi. 29:1012–1017. 2009.
18	Chunming J, Miao Z, Cheng S, et al: Tanshinone IIA attenuates peritoneal fibrosis through inhibition of fibrogenic growth factors expression in peritoneum in a peritoneal dialysis rat model. Ren Fail. 33:355–362. 2011.In Chinese. View Article : Google Scholar : PubMed/NCBI
19	Walters DM and Kleeberger SR: Mouse models of bleomycin-induced pulmonary fibrosis. Curr Protoc Pharmacol Chapter. 5:462008.
20	Wu Z, Yang L, Cai L, et al: Detection of epithelial to mesenchymal transition in airways of a bleomycin induced pulmonary fibrosis model derived from an alpha-smooth muscle actin-Cre transgenic mouse. Respir Res. 8:12007. View Article : Google Scholar : PubMed/NCBI
21	Ashcroft T, Simpson JM and Timbrell V: Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 41:467–470. 1988. View Article : Google Scholar : PubMed/NCBI
22	Hübner RH, Gitter W, El Mokhtari NE, et al: Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques. 44:507–511. 514–507. 2008. View Article : Google Scholar : PubMed/NCBI
23	Savas HA, Gergerlioglu HS, Armutcu F, et al: Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry. 7:51–55. 2006. View Article : Google Scholar : PubMed/NCBI
24	Dongaonkar RM, Laine GA, Stewart RH and Quick CM: Balance point characterization of interstitial fluid volume regulation. Am J Physiol Regul Integr Comp Physiol. 297:R6–R16. 2009. View Article : Google Scholar : PubMed/NCBI
25	Cheresh P, Kim SJ, Tulasiram S and Kamp DW: Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta. 1832:1028–1040. 2013. View Article : Google Scholar :
26	Greenhough A, Smartt HJ, Moore AE, et al: The COX‑2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 30:377–386. 2009. View Article : Google Scholar : PubMed/NCBI
27	Gawel S, Wardas M, Niedworok E and Wardas P: Malondialdehyde (MDA) as a lipid peroxidation marker. Wiad Lek. 57:453–455. 2004.In Polish.
28	Liu L, Lu W, Ma Z and Li Z: Oxymatrine attenuates bleomycin-induced pulmonary fibrosis in mice via the inhibition of inducible nitric oxide synthase expression and the TGF-β/Smad signaling pathway. Int J Mol Med. 29:815–822. 2012.PubMed/NCBI
29	Song JS, Kang CM, Kang HH, et al: Inhibitory effect of CXC chemokine receptor 4 antagonist AMD3100 on bleomycin induced murine pulmonary fibrosis. Exp Mol Med. 42:465–472. 2010. View Article : Google Scholar : PubMed/NCBI
30	Chen YL, Zhang X, Bai J, et al: Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial mesenchymal transition and fibroblast activation. Cell Death Dis. 4:e6652013. View Article : Google Scholar
31	Dong X, Dong J, Zhang R, Fan L, Liu L and Wu G: Anti-inflammatory effects of tanshinone IIA on radiation-induced microglia BV-2 cells inflammatory response. Cancer Biother Radiopharm. 24:681–687. 2009. View Article : Google Scholar : PubMed/NCBI
32	Fan GW, Gao XM, Wang H, et al: The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS. J Steroid Biochem Mol Biol. 113:275–280. 2009. View Article : Google Scholar : PubMed/NCBI
33	Fang J, Xu SW, Wang P, et al: Tanshinone II-A attenuates cardiac fibrosis and modulates collagen metabolism in rats with renovascular hypertension. Phytomedicine. 18:58–64. 2010. View Article : Google Scholar : PubMed/NCBI
34	Kinnula VL, Fattman CL, Tan RJ and Oury TD: Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med. 172:417–422. 2005. View Article : Google Scholar : PubMed/NCBI
35	Todd NW, Luzina IG and Atamas SP: Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair. 5:112012. View Article : Google Scholar : PubMed/NCBI
36	Chan P, Liu JC, Lin LJ, et al: Tanshinone IIA inhibits angiotensin II-induced cell proliferation in rat cardiac fibroblasts. Am J Chin Med. 39:381–394. 2011. View Article : Google Scholar : PubMed/NCBI
37	Zhang X, He D, Xu L and Ling S: Protective effect of tanshinone IIA on rat kidneys during hypothermic preservation. Mol Med Rep. 5:405–409. 2012.
38	Chiu TL and Su CC: Tanshinone IIA induces apoptosis in human lung cancer A549 cells through the induction of reactive oxygen species and decreasing the mitochondrial membrane potential. Int J Mol Med. 25:231–236. 2010.PubMed/NCBI
39	Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR and Grandjean P: Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem. 43:1209–1214. 1997.PubMed/NCBI
40	Jeon SJ, Son KH, Kim YS, Choi YH and Kim HP: Inhibition of prostaglandin and nitric oxide production in lipopolysaccharide-treated RAW 264.7 cells by tanshinones from the roots of Salvia miltiorrhizabunge. Arch Pharm Res. 31:758–763. 2008. View Article : Google Scholar : PubMed/NCBI
41	Sun D, Shen M, Li J, et al: Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3beta dependent pathway in experimental diabetic cardiomyopathy. Cardiovasc Diabetol. 10:42011. View Article : Google Scholar
42	Dong K, Xu W, Yang J, Qiao H and Wu L: Neuroprotective effects of Tanshinone IIA on permanent focal cerebral ischemia in mice. Phytother Res. 23:608–613. 2009. View Article : Google Scholar
43	Hsu YC, Wang LF and Chien YW: Nitric oxide in the pathogenesis of diffuse pulmonary fibrosis. Free Radic Biol Med. 42:599–607. 2007. View Article : Google Scholar : PubMed/NCBI
44	Genovese T, Cuzzocrea S, Di Paola R, et al: Inhibition or knock out of inducible nitric oxide synthase result in resistance to bleomycin-induced lung injury. Respir Res. 6:582005. View Article : Google Scholar : PubMed/NCBI
45	hen TH, Hsu YT, Chen CH, Kao SH and Lee HM: Tanshinone IIA from Salvia miltiorrhizainduces heme oxygenase-1 expression and inhibits lipopolysaccharide-induced nitric oxide expression in RAW 264.7 cells. Mitochondrion. 7:101–105. 2007. View Article : Google Scholar
46	Speyer CL, Neff TA, Warner RL, et al: Regulatory effects of iNOS on acute lung inflammatory responses in mice. Am J Pathol. 163:2319–2328. 2003. View Article : Google Scholar : PubMed/NCBI